TCGFB, a private biotech founded by healthcare VC The Column Group, is tapping California biotech Surrozen to discover antibodies for idiopathic pulmonary fibrosis, according to a Nov. 4 release.

Schematic representation of different strategies targeting TGF-β signaling for liver fibrosis therapy. TGF-β signaling inhibitors hold important therapeutic potential for hepatic fibrosis. Although ...

When it comes to cancer metastasis, it takes two to tango. That was one of the key findings of a new study led by researchers at Memorial Sloan Kettering Cancer Center (MSK): The TGF-beta and RAS ...

Transforming growth factor β1 (TGF-β1) is a key mediator of the fibrotic response and its dysregulation drives the formation of the fibrotic niche, which impairs the capacity of tissue repair, ...

An antibody that binds to the latent form of transforming growth factor-β1 (TGF-β1) prevented its release into the extracellular matrix and reduced the progression of fibrosis in the kidney. TGF-β is ...